Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2018 2
2019 6
2020 13
2021 21
2022 34
2023 43
2024 46
2025 33
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, Qureshi S, Cope AP, Norton S, Galloway JB. Yates M, et al. Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25. Arthritis Rheumatol. 2021. PMID: 33174384
OBJECTIVE: JAK inhibitor therapies are effective treatment options for immune-mediated inflammatory diseases (IMIDs), but their use has been limited by venous thromboembolism (VTE) risk warnings from licensing authorities. ...RESULTS: A total of 42 stu …
OBJECTIVE: JAK inhibitor therapies are effective treatment options for immune-mediated inflammatory diseases (IMIDs), but thei …
An update on VEXAS syndrome.
Al-Hakim A, Savic S. Al-Hakim A, et al. Expert Rev Clin Immunol. 2023 Feb;19(2):203-215. doi: 10.1080/1744666X.2023.2157262. Epub 2022 Dec 26. Expert Rev Clin Immunol. 2023. PMID: 36537591 Free article. Review.
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.
Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, Ytterberg SR, Hamar A, Fleischmann R. Szekanecz Z, et al. Nat Rev Rheumatol. 2024 Feb;20(2):101-115. doi: 10.1038/s41584-023-01062-9. Epub 2024 Jan 12. Nat Rev Rheumatol. 2024. PMID: 38216757 Review.
Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are increasingly used in the treatment of rheumatoid arthritis (RA). ...The registrational clinical trials and registry data of JAK inhibitors …
Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are increasingly …
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV Jr, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Danese S, et al. Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26. Lancet. 2022. PMID: 35644166 Clinical Trial.
We assessed the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. ...Events of cancer, adjudicated major adverse cardiac eve …
We assessed the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, as induction and maint …
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.
Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, Garshick MS. Ingrassia JP, et al. JAMA Dermatol. 2024 Jan 1;160(1):28-36. doi: 10.1001/jamadermatol.2023.4090. JAMA Dermatol. 2024. PMID: 37910098 Free PMC article.
IMPORTANCE: Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US Food and Drug Administration (FDA) boxed …
IMPORTANCE: Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-relat …
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P, Quera R, Yarur AJ. Núñez P, et al. Drugs. 2023 Mar;83(4):299-314. doi: 10.1007/s40265-023-01840-5. Epub 2023 Mar 13. Drugs. 2023. PMID: 36913180 Free PMC article. Review.
In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases (IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus kinase (JAK) inhibitors are a family of small molecules that block one …
In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases (IBD) has led to a relevant expansion of the therape …
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring.
Samuel C, Cornman H, Kambala A, Kwatra SG. Samuel C, et al. Dermatol Ther (Heidelb). 2023 Mar;13(3):729-749. doi: 10.1007/s13555-023-00892-5. Epub 2023 Feb 15. Dermatol Ther (Heidelb). 2023. PMID: 36790724 Free PMC article. Review.
Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions. ...Additionally, we offer suggestions for initial screening and laboratory monitoring for patients receiving JAK …
Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome de …
Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.
Solitano V, Ahuja D, Lee HH, Gaikwad R, Yeh KH, Facciorusso A, Singh AG, Ma C, Ananthakrishnan AN, Yuan Y, Singh N, Jairath V, Singh S. Solitano V, et al. JAMA Netw Open. 2025 Sep 2;8(9):e2531204. doi: 10.1001/jamanetworkopen.2025.31204. JAMA Netw Open. 2025. PMID: 40928778 Free PMC article.
IMPORTANCE: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). ...A random-effects meta-analysis was conducted to obtain incidence rates (IRs) and hazard ratios (HRs) for JAK …
IMPORTANCE: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammat …
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Burmester GR, et al. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735. RMD Open. 2023. PMID: 36754548 Free PMC article. Clinical Trial.
Deaths (0-0.8), serious infections (0-3.9), major adverse cardiovascular events (0-0.4), venous thromboembolism (<0.1-0.4) and malignancies (0.3-1.4) were observed, with rates generally lowest in AS and AD. ...
Deaths (0-0.8), serious infections (0-3.9), major adverse cardiovascular events (0-0.4), venous thromboembolism (<0.1-0.4) …
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC. Fleischmann R, et al. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28. Arthritis Rheumatol. 2019. PMID: 31287230 Clinical Trial.
OBJECTIVE: To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate re …
OBJECTIVE: To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selec …
201 results